Company Overview
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Key Highlights
- Biotechnology · Healthcare
- Led by Alon Ben-Noon
- 17 employees
- Based in Herzliya, TA
Price History
Loading…
Data from Twelve Data. Prices may be delayed.
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Nov 2
ISM Manufacturing PMI
10:00 AM ET
- Nov 4
ADP Employment Report
8:15 AM ET
- Nov 5
Initial Jobless Claims
8:30 AM ET
- Nov 6
Employment Situation (NFP)
8:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
76,832 −1.10%
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Herzliya, TA, IL
- Incorporated
- Dec 9, 2021
- Website
- www.neurosense-tx.com
Latest SEC Filings
View All Filings →- Foreign Issuer Report (Form 6-K)Nov 2, 2026
